Portfolio company 89bio was acquired by Roche in September 2025.
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases, focusing on the investigational glycopegylated FGF21 analog, pegozafermin
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases, focusing on the investigational glycopegylated FGF21 analog, pegozafermin.